Hologic Set to Report Q2 2025 Earnings with Cautious Analyst Outlook
Hologic, Inc. (HOLX), a prominent global medical technology firm headquartered in Marlborough, Massachusetts, is gearing up to announce its fiscal Q2 2025 earnings results on Thursday, May 1, after market close. Established in 1985, the company boasts a market capitalization of $12.9 billion and concentrates on diagnostic products, medical imaging systems, and surgical offerings, particularly in women’s health.
Anticipated Earnings and Forecasts
As the earnings release approaches, analysts project that Hologic will report a profit of $1.01 per share, reflecting a 1.9% decrease from the $1.03 per share recorded in the same quarter last year. The company has surpassed earnings expectations in three of the previous four quarters, though it fell short on one occasion.
Looking ahead to fiscal 2025, analysts predict Hologic will achieve an EPS of $4.27, marking a 4.7% increase from $4.08 in fiscal 2024. Furthermore, EPS growth for fiscal 2026 is estimated at 8.2%, projecting a rise to $4.62.
Stock Performance and Market Comparison
Over the past year, HOLX shares have underperformed compared to broader market indices, declining 23.2%. In contrast, the S&P 500 Index ($SPX) has gained 5.4%, while the Health Care Select Sector SPDR Fund (XLV) returned 2.1% during the same timeframe.
Recent Earnings and Future Guidance
On February 5, Hologic experienced a 10.1% drop in share price following its Q1 earnings announcement. The revenue for the quarter reached $1 billion, showing a slight year-over-year increase. The company’s adjusted EPS was $1.03, exceeding analyst expectations by 5.1%. The diagnostics segment thrived, particularly in molecular diagnostics, while the breast health segment faced challenges due to lower mammography equipment sales.
Investors expressed disappointment when Hologic revised its fiscal 2025 revenue forecast down to $4.05–$4.10 billion, down from the previous projection of $4.15–$4.20 billion. The revision was attributed to currency fluctuations and unexpected softness in the breast health equipment segment.
Analyst Ratings and Price Targets
Current analyst sentiment on HOLX is cautiously optimistic, reflecting a “Moderate Buy” consensus rating. Among the 19 analysts covering the stock, there are five “Strong Buys,” one “Moderate Buy,” and 13 “Holds.”
The average price target for Hologic is set at $80.06, suggesting a potential upside of 39.1% from current trading levels.
On the date of publication, Kritika Sarmah did not hold (either directly or indirectly) positions in any of the securities mentioned in this article. All information is for informational purposes only. For more details, please review the Barchart Disclosure Policy here.
More news from Barchart
The views and opinions expressed herein are those of the author and do not necessarily reflect those of Nasdaq, Inc.
